December 16th 2022, 1:00pm
Watch to Dr. Naveen Pemmaraju, from The University of Texas MD Anderson Cancer Center, discuss frontline treatment options for patients with myelofibrosis during the CURE® Educated Patient® MPN Summit.
December 15th 2022, 1:00pm
Watch Dr. Jamile Shammo and Dr. John Mascarenhas answer questions about polycythemia vera during the CURE Educated Patient MPN Summit.
December 14th 2022, 1:00pm
Watch Dr. John Mascarenhas, from the Icahn School of Medicine at Mount Sinai, discuss future treatments for polycythemia vera, during the CURE Educated Patient MPN Summit.
December 13th 2022, 1:00pm
Watch Dr. Jamile M. Shammo, from Northwestern University Feinberg School of Medicine, discuss current treatment options in polycythemia vera during the CURE Educated Patient MPN Summit.
December 12th 2022, 1:00pm
Watch Dr. Aaron Gerds and Dr. Douglas Tremblay answer questions about essential thrombocythemia during the CURE Educated Patient MPN Summit.
May 24th 2022, 1:00pm
Watch Dr. Jamile Shammo and Dr. Srdan Vestovsek answer questions about disease approaches during the CURE Educated Patient MPN Summit.
May 23rd 2022, 1:00pm
Watch Dr. Srdan Vestovsek, from The University of Texas MD Anderson Cancer Center, discuss novel agents and clinical trials in myelofibrosis, during the CURE Educated Patient MPN Summit.
May 22nd 2022, 2:00pm
Watch Dr. Jamile Shammo, from Rush University Medical Center, discuss differentiating an essential thrombocythemia diagnosis, during the CURE Educated Patient MPN Summit.
May 21st 2022, 2:00pm
Watch Dr. Jamile Shammo, Dr. Angela Fleishman and Kapila Viges answer questions about clinical trials during the CURE Educated Patient MPN Summit.
May 20th 2022, 1:00pm
Watch Kapila Viges, from the MPN Research Foundation, discuss clinical trials, during the CURE Educated Patient MPN Summit.
Zyprexa Added to Standard Antiemetics Reduces Nausea, Vomiting in Radiation
Sasanlimab-BCG Combo May Delay Recurrence in Bladder Cancer
Personalized Vaccine Elicits Responses in Patients With Kidney Cancer
The Invisibility of Blood Cancers to Others